Typical clinical features of Parkinson's disease (PD), a common movement disorder, include bradykinesia, rigidity, resting tremor, and gait disturbance. In addition to these well-known motor features, nonmotor symptoms such as depression, olfactory dysfunction, psychosis, and cognitive dysfunction are often detected early in PD. Olfactory dysfunction is used as a marker to detect the premotor stages of PD, as are other symptoms, such as depression, constipation, and REM sleep behavior disorder \[[@b1-jmd-18037],[@b2-jmd-18037]\]. Additionally, subtle cognitive changes are often detected in early PD patients \[[@b3-jmd-18037]\].

Serum uric acid (sUA) levels have been found to be a risk factor for some neurological diseases. That is, high sUA levels are known to increase the risk of both cardiovascular and cerebrovascular events \[[@b4-jmd-18037],[@b5-jmd-18037]\], whereas low sUA levels are found to be a risk factor for PD \[[@b6-jmd-18037]\]. Furthermore, some studies have shown that low sUA levels are associated with cognitive dysfunction in both healthy individuals and PD patients \[[@b7-jmd-18037],[@b8-jmd-18037]\].

To examine the hypothesis that sUA levels are associated with cognitive changes and olfactory dysfunction, we performed olfactory and comprehensive neuropsychological tests, including those for cognitive function and depression, in early *de novo* PD patients.

MATERIALS & METHODS
===================

Patients
--------

Between January 2015 and December 2017, patients presenting to the PD clinic of the Sanggye Paik Hospital for *de novo* PD were screened for enrollment in the study. All PD patients met the criteria of the UK Parkinson's Disease Society Brain Bank \[[@b9-jmd-18037]\]. We excluded those patients with diagnoses of secondary or atypical parkinsonism according to the available clinical criteria \[[@b10-jmd-18037]-[@b12-jmd-18037]\] and those patients diagnosed with major depression according to the fourth edition of the Diagnostic and Statistical Manual of Mental Disorders. For effective evaluation of olfactory function, patients who were current smokers were also excluded. All enrolled patients were admitted, and we obtained detailed information from the patients' history and neurological examinations. On admission, we classified the progression of symptoms into stages according to the Hoehn and Yahr scale (HY) \[[@b13-jmd-18037]\], and evaluated motor disability using the Unified Parkinson's Disease Rating Scale III (UPDRS-III) \[[@b14-jmd-18037]\]. Venous blood samples were drawn only at baseline in the morning after an overnight fast to evaluate UA levels. For this reason, we also excluded patients using treatments with diuretics or sUA-modifying agents and those with a body mass index \> 25 or \< 19 to exclude both over- and underweight patients. All patients provided signed informed consent. This study was approved by the Institutional Review Board of Sanggye Paik Hospital (IRB no. 201806008).

Neuropsychological assessment
-----------------------------

All enrolled patients underwent a detailed neuropsychological assessment by a psychologist. Cognitive function was evaluated by means of the Korean versions of the Mini-Mental State Examination (K-MMSE) and the Montreal Cognitive Assessment (K-MoCA). The current severity of any depressive episodes experienced by patients was evaluated using the Hamilton Depression Scale.

Korean version of the Sniffin' Sticks test
------------------------------------------

An otorhinolaryngologist examined all patients and excluded some patients with secondary anosmia, including obstruction. Olfactory function was examined by an otorhinolaryngologist using the Korean version of the Sniffin' Sticks test (KVSS II), which is a validated test instrument for Koreans \[[@b15-jmd-18037]\]. KVSS II consists of 16 different items with three components each, including olfactory threshold (i.e., detecting the lowest concentration of odor), odor discrimination (i.e., differentiating certain odors from several other odors), and odor identification (i.e., naming a certain odor). Using 16 pens, each filled with a different liquid odorant, the olfactory threshold and odor discrimination tests were carried out. Three pens (two with identical odors) were presented to each patient for odor discrimination. The odor identification test utilized all 16 odors. All patients were presented with the olfactory threshold test first, followed by the odor discrimination test and the odor identification test, with a break of 3 min between tests. The sums of the three tests are presented as threshold-discrimination-identification (TDI) scores. Total scores of 0 to 20 are defined as anosmia; 21 to 27, as hyposmia; and 28 to 48, as normosmia \[[@b15-jmd-18037]\].

Statistical analysis
--------------------

Data are expressed as the means (standard deviations) or numbers (percentages). Categorical data were examined by chi-square tests. Student's *t*-test was used to compare normally distributed data, and the Mann-Whitney U test was used to compare nonnormally distributed data. Pearson's and Spearman's correlation coefficients were calculated to evaluate the relationships between sUA levels and neuropsychological assessments. Multivariate linear regression models were used to analyze the association of significant univariate variables. Two-sided null hypotheses of no difference were rejected at *p* \< 0.05. SPSS Statistics 20 for Windows (IBM Corp, Armonk, NY, USA) was used for statistical analysis.

RESULTS
=======

During the trial, 286 patients were assessed, and 90 were excluded. Forty-six patients met exclusion criteria (including 32 patients with below middle school education and 5 using diuretics). Forty-four patients refused to participate in the study. Finally, a total of 196 participants met the inclusion criteria and were enrolled in this study ([Figure 1](#f1-jmd-18037){ref-type="fig"}). [Table 1](#t1-jmd-18037){ref-type="table"} shows the baseline characteristics of the enrolled patients. The mean age of the patients was 67.4 years, and 58% of the patients were women. The mean duration of disease at recruitment was 1.4 years. The mean HY stage was 1.7, and the mean total UPDRS (I--III) score was 34. There were no significant differences in these characteristics between men and women. The mean sUA level was 4.7 mg/dL and was significantly lower in women than in men (4.3 vs. 5.2 mg/dL, *p* \< 0.0001). The mean scores for TDI, MMSE and MoCA were 24.4, 25.7 and 21.7, respectively. These scores were lower in women than in men (TDI 22.1 vs. 26.0, p = 0.006, MMSE 24.8 vs. 27, *p* \< 0.0001 and MoCA 20.5 vs. 23.4, *p* \< 0.0001), suggesting that sUA was related to olfactory and cognitive function.

[Table 2](#t2-jmd-18037){ref-type="table"} shows the correlation analysis of sUA levels with the baseline characteristics. In all participants, sUA was significantly related to being female (*r* = -0.367), to MMSE scores (*r* = 0.222), and to MoCA scores (*r* = 0.215). Although there was no significant difference, a trend toward lower olfactory function (TDI score) was related to decreased sUA levels (r= 0.141, p = 0.064). sUA levels were clearly associated with MMSE and MoCA scores (*p* \< 0.008). TDI, olfactory threshold, odor discrimination, and odor identification scores were all significantly related to MMSE and MoCA scores (*r* \> 0.150, *p* \< 0.038). sUA was also significantly related to MMSE and MoCA scores in both male and female sexes (*p* \< 0.047). Multiple linear regression analysis revealed that age and sUA were significantly associated with MMSE and MoCA scores in all participants, with age being the most influential factor (β coefficients of -0.369 and 0.179 for age and sUA, respectively). [Figure 2](#f2-jmd-18037){ref-type="fig"} shows the age-adjusted scatterplots of the relationship between sUA levels and MMSE and MoCA scores. The sUA level was positively associated with MMSE and MoCA scores in patients with early *de novo* PD (*r* = 0.180, p = 0.017 for MMSE and *r* = 0.193, p = 0.010 for MoCA scores).

DISCUSSION
==========

In this study, we explored the relationships among sUA levels, cognitive function, and olfactory dysfunction. Our study clearly demonstrated that lower sUA levels were associated with more cognitive impairment in patients with *de novo* PD. We found that olfactory dysfunction was also related to cognitive decline. These findings support the hypothesis that UA is not neurotoxic as a pro-oxidant but is neuroprotective as an antioxidant \[[@b16-jmd-18037]\], as previous study results have suggested \[[@b8-jmd-18037],[@b17-jmd-18037],[@b18-jmd-18037]\].

Olfactory dysfunction and cognitive decline in early PD patients may be underestimated because there are many other causes of hyposmia and mild cognitive decline in elderly patients. Bohnen et al. \[[@b19-jmd-18037]\] first suggested a correlation between cognitive function and olfactory loss in PD patients, and since then several studies have shown that olfactory dysfunction is associated with cognitive impairment \[[@b20-jmd-18037]-[@b22-jmd-18037]\]. Recently, Park et al. \[[@b22-jmd-18037]\] showed that PD with minimal cognitive impairment is more likely to be associated with severe olfactory impairment than PD without cognitive dysfunction.

UA levels are considered a risk factor for cerebrovascular disease. Using MRI findings, Han et al. \[[@b23-jmd-18037]\] also showed that sUA was associated with cerebral white matter hyperintensities in patients with acute lacunar infarction. In terms of cognition, sUA levels reflect opposite findings in PD patients and healthy patients \[[@b8-jmd-18037],[@b18-jmd-18037]\], and high sUA levels are associated with cognitive deficits in a community of healthy individuals, excluding PD or Alzheimer disease (AD) patients. These results suggest that cerebrovascular disease causes cognitive decline in healthy people. However, low sUA levels have been observed in AD, vascular dementia, and PD patients with cognitive deficits. UA may play an important role in the pathophysiology of neurodegenerative disorders.

Based on this suggested mechanism, our study attempted to understand the relationship between sUA levels and olfactory dysfunction or cognitive dysfunction in PD patients. We found that sUA levels were positively related to cognitive function. A trend toward having lower olfactory function was related to decreased sUA levels in this study (*p* =0.064). Baba et al. \[[@b20-jmd-18037]\] showed that severe anosmia can be a prognostic marker of developing dementia in PD patients. Among the subtypes of olfactory tests, odor threshold and identification can be prodromal symptoms in patients with AD \[[@b24-jmd-18037]\]. Our finding that olfactory dysfunction was related to cognitive dysfunction in *de novo* early PD patients supports these previous results, demonstrating the correlation between olfaction and cognition in PD. In addition to olfaction and cognition, sUA can be associated with apathy, but not with depression, in *de novo* early PD patients \[[@b25-jmd-18037],[@b26-jmd-18037]\]. This result supported the mechanism that sUA levels and apathy are related to the loss of presynaptic dopaminergic innervation in the striatum in early *de novo* PD patients \[[@b27-jmd-18037],[@b28-jmd-18037]\]. Although we did not evaluate apathy, we found that sUA levels were unrelated to depression.

Our study has some limitations. Although we obtained a large sample size, we evaluated cognition using K-MMSE and K-MoCA rather than the detailed Neuropsychological Assessment Battery. For this reason, we could not identify the relationships between sUA levels and the subtypes of cognitive function, such as attention/executive function or visuoconstructional abilities. Additionally, as all enrolled participants were drug-naïve patients, we were unable to measure alterations in cognition and olfaction after drug therapy, including the use of levodopa or anti-UA drugs.

Despite these issues that limit our results, we discovered some unique findings through this study. We confirmed that lower sUA levels were associated with cognitive impairment in *de novo* PD patients. This finding suggests that UA is neuroprotective as an antioxidant for cognitive function in PD patients. However, we found no relationship between UA levels and olfactory function, despite the correlation between cognition and olfaction in PD patients. Therefore, the data from the current study support a relationship between sUA levels and cognition, but not between UA levels and olfaction or between UA levels and depression, in early *de novo* PD patients. Replications of our observations based on studies by independent cohorts are needed to confirm our findings.
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###### 

Baseline characteristics of enrolled patients

                              Total (*n*=196)   Men (*n*=83)   Women (*n*=113)   *p*-value
  --------------------------- ----------------- -------------- ----------------- ------------------------------------------------------
  Age (yr)                    67.4 (9.07)       66.2 (9.55)    68.4 (8.63)       0.089
  Duration (yr)               1.4 (1.24)        1.6 (1.46)     1.3 (1.05)        0.193
  HY stage                    1.7 (0.67)        1.7 (0.66)     1.7 (0.69)        0.402
  UPDRS I--III                34.0 (16.34)      35.9 (17.99)   32.5 (15.97)      0.360
  UPDRS-III                   21.6 (11.52)      21.5 (11.66)   21.6 (11.47)      0.979
  NMS                         39.6 (40.23)      37.2 (38.77)   41.4 (41.38)      0.480
  Olfactory functions                                                            
   Threshold                  6.7 (3.41)        6.7 (3.64)     6.7 (3.26)        0.994
   Discrimination             7.1 (3.15)        7.0 (3.35)     7.3 (3.01)        0.539
   Identification             6.7 (3.41)        6.7 (3.64)     6.7 (3.26)        0.994
   TDI score (normosmia≥28)   24.4 (9.91)       26.0 (9.12)    22.1 (10.55)      0.006^[\*](#tfn1-jmd-18037){ref-type="table-fn"}^
  MMSE score                  25.7 (3.91)       27.0 (2.85)    24.8 (4.30)       \<0.0001^[\*](#tfn1-jmd-18037){ref-type="table-fn"}^
  MoCA score                  21.7 (5.62)       23.4 (4.41)    20.5 (6.09)       \<0.0001^[\*](#tfn1-jmd-18037){ref-type="table-fn"}^
  HAM-D                       8.9 (6.87)        9.0 (7.08)     8.7 (6.74)        0.802
  PDSS                        92.7 (40.84)      98.9 (36.71)   88.1 (43.23)      0.088
  BMI (kg/m^2^)               23.6 (3.04)       23.6 (2.90)    23.7 (3.14)       0.911
  Serum uric acid (mg/dL)     4.7 (1.16)        5.2 (1.22)     4.3 (0.94)        \<0.0001^[\*](#tfn1-jmd-18037){ref-type="table-fn"}^

Data are presented as the mean (SD).

significant *p*-values.

HY: Hoehn and Yahr, UPDRS: Unified Parkinson's Disease Rating Scale, UPDRS-III: Unified Parkinson's Disease Rating Scale Part III, NMS: Non-Motor Symptom Scale, TDI: threshold-discrimination-identification, MMSE: Mini-Mental State Examination, MoCA: Montreal Cognitive Assessment, HAM-D: Hamilton Depression Rating Scale, PDSS: Parkinson's Disease Sleep Scale, BMI: body mass index.

###### 

Correlation analysis of sUA level with baseline characteristics

                        sUA level                                                                                                                                
  --------------------- ----------- ------------------------------------------------------ -------- --------------------------------------------------- -------- ---------------------------------------------------
  Age                   -0.112      0.139                                                  -0.185   0.094                                               -0.122   0.254
  Female                -0.367      \<0.0001^[\*](#tfn2-jmd-18037){ref-type="table-fn"}^                                                                         
  Disease duration      -0.125      0.097                                                  -0.223   0.051                                               -0.075   0.459
  HY stage              -0.124      0.137                                                  -0.174   0.134                                               -0.112   0.272
  UPDRS I--III          -0.102      0.179                                                  -0.143   0.218                                               -0.021   0.834
  UPDRS III             -0.103      0.178                                                  -0.214   0.074                                               -0.019   0.854
  NMS                   -0.143      0.156                                                  -0.112   0.211                                               -0.088   0.392
  Olfactory functions                                                                                                                                            
   Threshold            -0.015      0.840                                                  0.092    0.435                                               -0.086   0.401
   Discrimination       -0.086      0.260                                                  0.092    0.435                                               0.086    0.401
   Identification       0.002       0.978                                                  -0.018   0.879                                               -0.119   0.243
  TDI score             0.141       0.064                                                  0.211    0.079                                               0.236    0.054
  MMSE                  0.222       0.003^[\*](#tfn2-jmd-18037){ref-type="table-fn"}^      0.233    0.041^[\*](#tfn2-jmd-18037){ref-type="table-fn"}^   0.229    0.047^[\*](#tfn2-jmd-18037){ref-type="table-fn"}^
  MoCA                  0.215       0.004^[\*](#tfn2-jmd-18037){ref-type="table-fn"}^      0.237    0.039^[\*](#tfn2-jmd-18037){ref-type="table-fn"}^   0.231    0.042^[\*](#tfn2-jmd-18037){ref-type="table-fn"}^
  HAM-D                 -0.124      0.121                                                  -0.198   0.102                                               -0.137   0.203
  PDSS                  0.127       0.113                                                  0.148    0.270                                               0.054    0.619
  BMI                   0.186       0.063                                                  0.171    0.293                                               0.172    0.188

significant *p*-values.

sUA: serum uric acid, HY: Hoehn and Yahr, UPDRS: Unified Parkinson's Disease Rating Scale, UPDRS-III: Unified Parkinson's Disease Rating Scale part III, NMS: Non-Motor Symptom Scale, TDI: threshold-discrimination-identification, MMSE: Mini-Mental State Examination, MoCA: Montreal Cognitive Assessment, HAM-D: Hamilton Depression Rating Scale, PDSS: Parkinson's Disease Sleep Scale, BMI: body mass index.
